<!DOCTYPE html>

<html lang="en" data-theme="light">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Aspects of Pharmacotherapy - Essentials of Medical Pharmacology</title>

<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">

<link rel="stylesheet" href="../styles/main.css">

<script>
MathJax = {
    tex: {
        inlineMath: [['$', '$'], ['\\(', '\\)']],
        displayMath: [['$$', '$$'], ['\\[', '\\]']],
        processEscapes: true,
        processEnvironments: true
    },
    svg: { fontCache: 'global' },
    options: {
        skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
    }
};
</script>
<script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
<a href="#main-content" class="skip-link">Skip to main content</a>

<button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
    <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
    <span class="theme-toggle-icon dark-icon">üåô</span>
</button>

<div class="reading-progress-container">
    <div class="reading-progress-bar" id="reading-progress"></div>
</div>

<!-- Floating TOC -->
<nav class="floating-toc" id="floating-toc">
    <div class="floating-toc-header">
        <span>üìë</span> Table of Contents
    </div>
    <ul class="floating-toc-list">
        <li><a href="#drug-dosage">Drug Dosage</a></li>
        <li><a href="#fixed-dose-combinations">Fixed Dose Combinations</a></li>
        <li><a href="#factors-modifying">Factors Modifying Action</a></li>
        <li><a href="#pharmacogenetics">Pharmacogenetics</a></li>
        <li><a href="#pathological-states">Pathological States</a></li>
        <li><a href="#tolerance">Tolerance</a></li>
        <li><a href="#rational-use">Rational Use of Medicines</a></li>
        <li><a href="#evidence-based">Evidence-Based Medicine</a></li>
        <li><a href="#drug-development">New Drug Development</a></li>
    </ul>
</nav>

<div class="page-wrapper">
    <div class="container">
        <article class="document-article">
            <header class="document-header">
                <div class="header-badge">
                    <span>üíä</span>
                    <span>Topic 05</span>
                </div>
                <h1 class="document-title">Aspects of Pharmacotherapy, Clinical Pharmacology and Drug Development</h1>
                <div class="title-meta">
                    <div class="meta-item">
                        <span>üìö</span>
                        <span>General Pharmacological Principles</span>
                    </div>
                    <div class="meta-item">
                        <span>‚è±Ô∏è</span>
                        <span>30 min read</span>
                    </div>
                </div>
            </header>

            <main id="main-content" class="content-wrapper">
                <!-- Section 1: Drug Dosage -->
                <section class="content-section" id="drug-dosage">
                    <div class="section-header">
                        <div class="section-number">01</div>
                        <h2 class="section-title">
                            <span class="title-icon">üìè</span>
                            Drug Dosage
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>'Dose' is the appropriate amount of a drug needed to produce a certain degree of response in a given patient. Accordingly, dose of a drug has to be qualified in terms of the chosen response, e.g. the analgesic dose of aspirin for headache is $0.3-0.6 \text{ g}$, its antiplatelet dose is $60-150 \text{ mg/day}$, while its antiinflammatory dose for rheumatoid arthritis is $3-5 \text{ g}$ per day. Similarly there could be a prophylactic dose, a therapeutic dose or a toxic dose of the same drug.</p>
                        
                        <p>The strategies adopted for different types of drugs and conditions are:</p>
                        
                        <div class="grid grid-2">
                            <div class="grid-item">
                                <h4>1. Standard dose</h4>
                                <p>The same dose is appropriate for most patients‚Äîindividual variations are minor or the drug has a wide safety margin so that a large enough dose can be given to cover them, e.g. oral contraceptives, penicillin, chloroquine, mebendazole, hydrochlorothiazide.</p>
                            </div>
                            <div class="grid-item">
                                <h4>2. Regulated dose</h4>
                                <p>The drug modifies a finely regulated body function which can be easily measured. The dosage is accurately adjusted by repeated measurement of the affected physiological parameter, e.g. antihypertensives, hypoglycaemics, anticoagulants, diuretics, general anaesthetics. In their case, measurement of plasma drug concentration is not needed.</p>
                            </div>
                            <div class="grid-item">
                                <h4>3. Target level dose</h4>
                                <p>The response is not easily measurable but has been demonstrated to be obtained at a certain range of drug concentration in plasma. An empirical dose aimed at attaining the target level is given in the beginning and adjustments are made later by actual monitoring of plasma concentrations. When facilities for drug level monitoring are not available, crude adjustments are made by observing the patient at relatively long intervals, e.g. antidepressants, antiepileptics, digoxin, theophylline.</p>
                            </div>
                            <div class="grid-item">
                                <h4>4. Titrated dose</h4>
                                <p>The dose needed to produce maximal therapeutic effect cannot be given because of intolerable adverse effects. Optimal dose is arrived at by titrating it with an acceptable level of adverse effect. Low initial dose and upward titration (in most non-critical situations) or high initial dose and downward titration (in critical situations) can be practised. Often a compromise between submaximal therapeutic effect but tolerable side effects can be struck, e.g. anticancer drugs, corticosteroids, levodopa.</p>
                            </div>
                        </div>
                    </div>
                </section>

                <!-- Section 2: Fixed Dose Combinations -->
                <section class="content-section" id="fixed-dose-combinations">
                    <div class="section-header">
                        <div class="section-number">02</div>
                        <h2 class="section-title">
                            <span class="title-icon">üíä</span>
                            Fixed Dose Combinations (FDCs)
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>A large number of pharmaceutical preparations contain two or more drugs in a fixed dose ratio.</p>

                        <h3>Advantages</h3>
                        <ul class="enhanced-list">
                            <li class="list-item"><span class="list-marker">1</span> Convenience and better patient compliance‚Äîwhen all the components present in the FDC are actually needed by the patient and their amounts are appropriate. It may also be cost saving compared to both/all the components administered separately.</li>
                            <li class="list-item"><span class="list-marker">2</span> Certain drug combinations are synergistic, e.g. sulfamethoxazole + trimethoprim; levodopa + carbidopa/benserazide; combination oral contraceptives, isoniazid + rifampin.</li>
                            <li class="list-item"><span class="list-marker">3</span> The therapeutic effect of two components being same may add up while the side effects being different may not. For this the components of the FDC should act by different mechanisms, e.g. amlodipine + atenolol as antihypertensive.</li>
                            <li class="list-item"><span class="list-marker">4</span> The side effect of one component may be counteracted by the other, e.g. a thiazide + a potassium sparing diuretic. However, the amount of the latter may not be sufficient in all cases.</li>
                            <li class="list-item"><span class="list-marker">5</span> Combined formulation ensures that a single drug will not be administered. This is important in the treatment of tuberculosis, HIV-AIDS and falciparum malaria.</li>
                        </ul>

                        <div class="callout callout--warning">
                            <div class="callout-header">
                                <span class="callout-icon">‚ö†Ô∏è</span>
                                <h4 class="callout-title">Disadvantages of FDCs</h4>
                            </div>
                            <div class="callout-content">
                                <ol>
                                    <li>The patient may not actually need all the drugs present in a combination: he is subjected to additional side effects and expense.</li>
                                    <li>The dose of most drugs needs to be adjusted and individualised. When a combined formulation is used, this cannot be done without altering the dose of the other component(s).</li>
                                    <li>The time course of action of the components may be different: administering them at the same intervals may be inappropriate.</li>
                                    <li>Altered renal or hepatic function of the patient may differently affect the pharmacokinetics of the components.</li>
                                    <li>Adverse effect, when it occurs, cannot be easily ascribed to the particular drug causing it.</li>
                                    <li>Contraindication to one component (allergy, other conditions) contraindicates the whole product.</li>
                                    <li>Confusion of therapeutic aims and false sense of superiority of two drugs over one is fostered.</li>
                                </ol>
                            </div>
                        </div>
                    </div>
                </section>

                <!-- Section 3: Factors Modifying Drug Action -->
                <section class="content-section" id="factors-modifying">
                    <div class="section-header">
                        <div class="section-number">03</div>
                        <h2 class="section-title">
                            <span class="title-icon">üß¨</span>
                            Factors Modifying Drug Action
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>Variation in response to the same dose of a drug between different patients and even in the same patient on different occasions is a rule rather than exception. The factors modify drug action either:</p>
                        <ul>
                            <li><strong>Quantitatively:</strong> The plasma concentration and/or the action of the drug is increased or decreased.</li>
                            <li><strong>Qualitatively:</strong> The type of response is altered, e.g. drug allergy or idiosyncrasy.</li>
                        </ul>

                        <h4>1. Body size</h4>
                        <p>For exceptionally obese or lean individuals and for children dose may be calculated on body weight (BW) basis:</p>
                        <div class="equation">
                            $$\text{Individual dose} = \frac{\text{BW (kg)}}{70} \times \text{average adult dose}$$
                        </div>
                        <p>Body surface area (BSA) provides a more accurate basis for dose calculation. The BSA of an individual can be calculated from Dubois formula:</p>
                        <div class="equation">
                            \begin{aligned}
                            \text{Individual dose} &= \frac{\text{BSA } (\mathrm{m}^{2})}{1.7} \times \text{average adult dose} \\
                            \text{BSA } (\mathrm{m}^{2}) &= \text{BW } (\mathrm{kg})^{0.425} \times \text{Height } (\mathrm{cm})^{0.725} \times 0.007184
                            \end{aligned}
                        </div>

                        <h4>2. Age</h4>
                        <p>The dose of a drug for children is often calculated from the adult dose. Child dose is better calculated more accurately on BW basis. For many drugs, manufacturers give dosage recommendations on $\text{mg/kg}$ basis. However, infants and children are not small adults. The newborn has low g.f.r. and tubular transport is immature. Similarly, hepatic drug metabolizing system is inadequate in newborns. Blood-brain barrier is more permeable.</p>
                        <p><strong>Elderly:</strong> Renal function progressively declines (intact nephron loss) so that g.f.r. is $\sim 75\%$ at 50 years and $\sim 50\%$ at 75 years age compared to young adults. There is also a reduction in the hepatic microsomal drug metabolizing activity and liver blood flow. Elderly are also likely to be on multiple drug therapy which increases many fold the chances of drug interactions. They are more prone to develop postural instability, giddiness and mental confusion. In general, the incidence of adverse drug reactions is much higher in the elderly.</p>

                        <h4>3. Sex</h4>
                        <p>Females have smaller body size and require doses that are on the lower side of the range. Drugs given during pregnancy can affect the foetus. There are marked and progressive physiological changes during pregnancy, especially in the third trimester, which can alter drug disposition (delayed absorption, increased volume of distribution, altered protein binding, increased renal blood flow, hepatic enzyme induction).</p>

                        <h4>4. Species and race</h4>
                        <p>Rabbits are resistant to atropine, rats and mice are resistant to digitalis. Blacks require higher and Mongols require lower concentrations of atropine and ephedrine to dilate their pupil. $\beta$-blockers are less effective as antihypertensive in Afro-Caribbeans.</p>

                        <h4 id="pharmacogenetics">5. Genetics (Pharmacogenetics)</h4>
                        <p>The study of genetic basis for variability in drug response is called 'Pharmacogenetics'. It deals with genetic influences on drug action as well as on drug handling by the body.</p>
                        <div class="table-responsive">
                            <table class="comparison-table">
                                <thead>
                                    <tr>
                                        <th colspan="2">Drugs with potential to cause haemolysis in G-6PD deficient individuals</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Primaquine</td>
                                        <td>Nalidixic acid</td>
                                    </tr>
                                    <tr>
                                        <td>Chloroquine</td>
                                        <td>Fluoroquinolones</td>
                                    </tr>
                                    <tr>
                                        <td>Quinine/Quinidine</td>
                                        <td>Chloramphenicol</td>
                                    </tr>
                                    <tr>
                                        <td>Proguanil</td>
                                        <td>Nitrofurantoin</td>
                                    </tr>
                                    <tr>
                                        <td>Pyrimethamine</td>
                                        <td>Furazolidone</td>
                                    </tr>
                                    <tr>
                                        <td>Dapsone</td>
                                        <td>Menadione</td>
                                    </tr>
                                    <tr>
                                        <td>Sulfonamides</td>
                                        <td>Methyldopa</td>
                                    </tr>
                                    <tr>
                                        <td>Cotrimoxazole</td>
                                        <td>Hydralazine</td>
                                    </tr>
                                    <tr>
                                        <td>Sulfasalazine</td>
                                        <td>Procainamide</td>
                                    </tr>
                                    <tr>
                                        <td>Sulfonylureas</td>
                                        <td>Probenecid</td>
                                    </tr>
                                    <tr>
                                        <td>Thiazide diuretics</td>
                                        <td>Colchicine</td>
                                    </tr>
                                    <tr>
                                        <td>Aspirin</td>
                                        <td>Methylene blue</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h4>6. Route of administration</h4>
                        <p>Route of administration governs the speed and intensity of drug response. Parenteral administration is often resorted to for more rapid, more pronounced and more predictable drug action.</p>

                        <h4>7. Environmental factors and time of administration</h4>
                        <p>Exposure to insecticides, carcinogens, tobacco smoke and consumption of charcoal broiled meat induce drug metabolism. Type of diet and temporal relation between drug ingestion and meals can alter drug absorption. Hypnotics taken at night and in quiet, familiar surroundings may work more easily.</p>

                        <h4>8. Psychological factor</h4>
                        <p><strong>Placebo:</strong> An inert substance which is given in the garb of a medicine. It works by psychodynamic rather than pharmacodynamic means and often produces responses equivalent to the active drug.</p>
                        <p><strong>Nocebo:</strong> It is the converse of placebo, and refers to negative psychodynamic effect evoked by the pessimistic attitude of the patient.</p>

                        <h4 id="pathological-states">9. Pathological states</h4>
                        <p><strong>Gastrointestinal diseases:</strong> Can alter absorption of orally administered drugs. Achlorhydria decreases aspirin absorption by favouring its ionization.</p>
                        <p><strong>Liver disease:</strong> Bioavailability of drugs having high first pass metabolism is increased. Serum albumin is reduced‚Äîprotein binding of acidic drugs is reduced. Metabolism and elimination of some drugs is decreased.</p>
                        <p><strong>Kidney disease:</strong> Clearance of drugs that are primarily excreted unchanged (aminoglycosides, digoxin, phenobarbitone) is reduced parallel to decrease in creatinine clearance $(\mathrm{CL}_{\mathrm{cr}})$.</p>

                        <div class="table-responsive">
                            <table class="comparison-table">
                                <thead>
                                    <tr>
                                        <th>Antimicrobials needing dose reduction in renal failure</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td><strong>Even in mild failure:</strong> Aminoglycosides, Cephalexin, Ethambutol, Vancomycin, Amphotericin B, Acyclovir</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Only in severe failure:</strong> Cotrimoxazole, Carbenicillin, Cefotaxime, Norfloxacin, Ciprofloxacin, Metronidazole</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h4>10. Other drugs</h4>
                        <p>Drugs can modify the response to each other by pharmacokinetic or pharmacodynamic interaction between them.</p>

                        <h4>11. Cumulation</h4>
                        <p>Any drug will cumulate in the body if rate of administration is more than the rate of elimination. Slowly eliminated drugs are particularly liable to cause cumulative toxicity, e.g. prolonged use of chloroquine causes retinal damage.</p>

                        <h4 id="tolerance">12. Tolerance</h4>
                        <p>It refers to the requirement of higher dose of a drug to produce a given response. Tolerance is a widely occurring adaptive biological phenomenon. Loss of therapeutic efficacy after prolonged/intensive use of a drug is generally called 'refractoriness'.</p>
                        <ul class="enhanced-list">
                            <li class="list-item"><span class="list-marker"></span> <strong>Natural:</strong> The species/individual is inherently less sensitive to the drug.</li>
                            <li class="list-item"><span class="list-marker"></span> <strong>Acquired:</strong> Occurs by repeated use of a drug in an individual who was initially responsive.</li>
                            <li class="list-item"><span class="list-marker"></span> <strong>Cross tolerance:</strong> It is the development of tolerance to pharmacologically related drugs.</li>
                            <li class="list-item"><span class="list-marker"></span> <strong>Tachyphylaxis:</strong> (Tachy‚Äîfast, phylaxis‚Äîprotection) It refers to rapid development of tolerance when doses of a drug repeated in quick succession result in marked reduction in response (e.g., ephedrine, tyramine).</li>
                        </ul>
                    </div>
                </section>

                <!-- Section 4: Rational Use of Medicines -->
                <section class="content-section" id="rational-use">
                    <div class="section-header">
                        <div class="section-number">04</div>
                        <h2 class="section-title">
                            <span class="title-icon">ü©∫</span>
                            Rational Use of Medicines
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>As per the WHO ‚Äì 'rational use of medicines requires that the patients receive medication appropriate to their clinical needs, in doses that meet their own individual requirements for an adequate period of time, and at the lowest cost to them and to their community'.</p>

                        <h3>Process of rational prescribing</h3>
                        <ul class="enhanced-list">
                            <li class="list-item"><span class="list-marker">1</span> Establish a diagnosis (at least provisional).</li>
                            <li class="list-item"><span class="list-marker">2</span> Define therapeutic problem(s), e.g. pain, infection.</li>
                            <li class="list-item"><span class="list-marker">3</span> Define therapeutic goals to be achieved.</li>
                            <li class="list-item"><span class="list-marker">4</span> Select the class of drug capable of achieving each goal.</li>
                            <li class="list-item"><span class="list-marker">5</span> Identify the drug (from the class selected) based on Efficacy, Safety, Suitability, Cost.</li>
                            <li class="list-item"><span class="list-marker">6</span> Decide the route, dose, duration of treatment.</li>
                            <li class="list-item"><span class="list-marker">7</span> Provide proper information and instructions about the medication.</li>
                            <li class="list-item"><span class="list-marker">8</span> Monitor adherence to the medication.</li>
                            <li class="list-item"><span class="list-marker">9</span> Monitor the extent to which therapeutic goal is achieved.</li>
                            <li class="list-item"><span class="list-marker">10</span> Monitor any adverse drug events that occur.</li>
                        </ul>

                        <details class="collapsible-section">
                            <summary class="collapsible-trigger">
                                <span class="trigger-icon">‚ñ∂</span>
                                <span class="trigger-text">Irrationalities in prescribing</span>
                            </summary>
                            <div class="collapsible-content">
                                <ul>
                                    <li>Use of drug when none is needed (e.g. antibiotics for viral fevers).</li>
                                    <li>Compulsive coprescription of vitamins/tonics.</li>
                                    <li>Use of drugs not related to the diagnosis.</li>
                                    <li>Selection of wrong drug.</li>
                                    <li>Prescribing ineffective/doubtful efficacy drugs.</li>
                                    <li>Incorrect route of administration.</li>
                                    <li>Incorrect dose.</li>
                                    <li>Incorrect duration of treatment.</li>
                                    <li>Unnecessary use of drug combinations.</li>
                                    <li>Unnecessary use of expensive medicines when cheaper drugs are equally effective.</li>
                                    <li>Unsafe use of drugs.</li>
                                    <li>Polypharmacy without regard to drug interactions.</li>
                                </ul>
                            </div>
                        </details>
                    </div>
                </section>

                <!-- Section 5: Evidence-Based Medicine -->
                <section class="content-section" id="evidence-based">
                    <div class="section-header">
                        <div class="section-number">05</div>
                        <h2 class="section-title">
                            <span class="title-icon">üìä</span>
                            Evidence-Based Medicine
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>Evidence-based medicine is the process of systematically finding, evaluating and using contemporary research findings as the basis of clinical decisions.</p>

                        <h3>Clinical trial</h3>
                        <p>Clinical trial is a prospective ethically designed investigation in human subjects to objectively discover/verify/compare the results of two or more therapeutic measures (drugs). The credibility of the trial depends on measures like <strong>Randomization</strong> and <strong>Blinding (masking)</strong>.</p>

                        <div class="table-responsive">
                            <table class="comparison-table">
                                <thead>
                                    <tr>
                                        <th>Grades of strength of evidence</th>
                                        <th>Description</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td><strong>Grade I</strong></td>
                                        <td>Systematic reviews/Meta-analysis. Most reliable.</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Grade II</strong></td>
                                        <td>Well powered randomized controlled trial/more than one trials. Reliable.</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Grade III</strong></td>
                                        <td>Open label trials/pilot studies/observational (cohort and case-control) studies. Less reliable.</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Grade IV</strong></td>
                                        <td>Case reports/anecdotal reports/clinical experience. Least reliable.</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </section>

                <!-- Section 6: New Drug Development -->
                <section class="content-section" id="drug-development">
                    <div class="section-header">
                        <div class="section-number">06</div>
                        <h2 class="section-title">
                            <span class="title-icon">üÜï</span>
                            New Drug Development
                        </h2>
                    </div>

                    <div class="content-card">
                        <div class="grid grid-2">
                            <div class="grid-item">
                                <h4>Stages in new drug development</h4>
                                <ul class="enhanced-list">
                                    <li class="list-item"><strong>Synthesis/isolation:</strong> 1-2 years</li>
                                    <li class="list-item"><strong>Preclinical studies:</strong> 2-4 years</li>
                                    <li class="list-item"><strong>Scrutiny/permission:</strong> 3-6 months</li>
                                    <li class="list-item"><strong>Pharmaceutical formulation:</strong> 0.5-1 year</li>
                                    <li class="list-item"><strong>Clinical studies (Phase I, II, III):</strong> 3-10 years</li>
                                    <li class="list-item"><strong>Review/marketing permission:</strong> 0.5-2 years</li>
                                    <li class="list-item"><strong>Postmarketing surveillance:</strong> Phase IV</li>
                                </ul>
                            </div>
                            <div class="grid-item">
                                <h4>Clinical Trials Phases</h4>
                                <ul>
                                    <li><strong>Phase 0:</strong> Microdosing study.</li>
                                    <li><strong>Phase I:</strong> Human pharmacology and safety (healthy volunteers).</li>
                                    <li><strong>Phase II:</strong> Therapeutic exploration and dose ranging (patients).</li>
                                    <li><strong>Phase III:</strong> Therapeutic confirmation/comparison (large patient population).</li>
                                    <li><strong>Phase IV:</strong> Postmarketing surveillance/data gathering.</li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </section>

                <!-- Problem Directed Study -->
                <section class="content-section" id="problem-study">
                    <div class="section-header">
                        <div class="section-number">07</div>
                        <h2 class="section-title">
                            <span class="title-icon">üß©</span>
                            Problem Directed Study
                        </h2>
                    </div>

                    <div class="content-card">
                        <div class="callout callout--warning">
                            <div class="callout-header">
                                <span class="callout-icon">‚ùì</span>
                                <h4 class="callout-title">Case Study 5.1</h4>
                            </div>
                            <div class="callout-content">
                                <p>A 65-year-old male hepatic cirrhosis patient was admitted to the hospital for treatment of gross ascites. He was administered inj. furosemide 40 mg i.m. three times a day to excrete the ascitic fluid. He responded with brisk diuresis, but on the 3rd day he was found to be talking irrelevant, was weak and partly disoriented. He had a fainting episode on getting up from the bed. His serum $\mathrm{K}^{+}$ was $2.8 \mathrm{mEq} / \mathrm{L}$ (low) and blood pH was 7.6 (raised).</p>
                                <p><strong>(a) What is the likely cause of his condition on the 3rd day?</strong></p>
                                <p><strong>(b) What should be the principles of management of this complication?</strong></p>
                                <p><em>(See Appendix-1 for solution)</em></p>
                            </div>
                        </div>
                    </div>
                </section>

            </main>

            <nav class="document-nav">
                <div class="nav-container">
                    <a href="topic-04-pharmacodynamics.html" class="nav-button nav-button--large nav-button--previous">
                        <div class="nav-label">Previous</div>
                        <div class="nav-title">Pharmacodynamics</div>
                    </a>
                    
                    <div class="document-progress">
                        <div class="progress-indicator">
                            <span>5</span>
                            <span class="progress-separator">/</span>
                            <span>13</span>
                        </div>
                        <div class="progress-bar-container">
                            <div class="progress-bar-fill" style="width: 38.4%;"></div>
                        </div>
                        <div class="progress-label">Topic Progress</div>
                    </div>
                    
                    <a href="topic-06-adverse-effects.html" class="nav-button nav-button--large nav-button--next">
                        <div class="nav-label">Next</div>
                        <div class="nav-title">Adverse Drug Effects</div>
                    </a>
                </div>
            </nav>
        </article>
    </div>
</div>

<script src="../js/theme.js"></script>
<script src="../js/navigation.js"></script>
<script src="../js/interactions.js"></script>
</body>
</html>
